Radioisotope manufacturer International Isotopes reported a 5% increase in revenues for 2020.
In the period (end-December 31), total revenues were about $9.3 million compared with approximately $8.9 million in 2019. Sales grew 43% in the company's radiochemical segment thanks to U.S. Food and Drug Administration approval in February 2020 of its abbreviated new drug application for sodium iodide I-131.
The company also reached its highest level of net income in company history in 2020. Net income was about $2.2 million in 2020 compared with a net loss of approximately $1.5 million in 2019.
